FDA Oversight Fails as Nearly 1 Million Heart Pills Recalled
Amgen recalls nearly one million bottles of heart and kidney medications after inspectors found foreign substances on tablets, exposing systemic failures in FDA oversight of foreign drug manufacturing.
Heart failure patients and kidney disease sufferers face another round of uncertainty after Amgen recalled nearly one million bottles of medication last month. Inspectors discovered an unidentified foreign substance on tablets manufactured overseas. The Food and Drug Administration classified the recall as Class II, meaning the contaminated drugs may cause temporary or medically reversible adverse health consequences.
The recall of 944,142 bottles of Corlanor and Sensipar tablets, produced in Italy and Japan, exposes systemic failures in American drug safety oversight. Drug recalls have surged in recent years, while federal regulators struggle to inspect foreign manufacturing plants supplying the U.S. market.
Amgen voluntarily withdrew 934,577 bottles of Corlanor heart failure medication and 9,565 bottles of Sensipar kidney disease treatment after discovering unexpected foreign matter localized on tablet surfaces. The drugs, distributed between October 2021 and December 2025, originated in Italy and Japan.
"As a precaution, Amgen is voluntarily recalling all lots of Corlanor and Sensipar Tablets within expiry from retail pharmacies in the United States," a company spokesperson stated.
This recall represents not an isolated incident but a symptom of a regulatory system failing to match inspection capacity with overseas pharmaceutical production. China and India together supply a large share of active pharmaceutical ingredients, though the exact figure varies by drug category and measurement method.
The FDA conducts roughly 12,000 domestic inspections annually but only 3,000 overseas inspections across 90 countries. Approximately 90 percent of those inspections arrive announced in advance. That advance notice gives foreign manufacturers time to conceal compliance issues before regulators walk through their doors.
Overall FDA product recalls jumped from 22 in 2018 to 310 in 2022, a 14-fold increase according to STAT news data cited by the Heritage Foundation. Sixty-six percent of all recalls fall into Class II, with mispackaging, contamination and potency issues as top causes.
Generics manufactured in India carry 54.3 percent more serious adverse events than U.S.-made versions, a University of Connecticut study found. The Heritage Foundation reports the FDA independently collects and tests only about 0.001 percent of imported drugs.
India's Dabur Limited facility joined the growing list of violations when the FDA placed it on Import Alert June 5 for falsified records, inadequate testing and maintenance violations.
"Even the US Government Accountability Office publicly criticized the FDA in February 2026 about inspection effectiveness," said Dr. David Gortler, a former FDA official writing for the Brownstone Journal. "Today, hardly a weekday goes by at the FDA where they don't announce at least one recall."
The inspection backlog numbered in the thousands before the 2024 election and persists into 2026. The agency's announced inspection approach gives foreign manufacturers time to conceal compliance issues before regulators arrive.
Amgen stated the foreign matter represented low potential health risk to patients, and no complaints have been reported. Both drugs have been discontinued by Amgen, though generic versions remain available. Corlanor lowers heart rate without reducing blood pressure for chronic heart failure patients, while Sensipar treats high blood calcium in kidney disease patients.
The Brookings Institution analysis notes the FDA faces a too important to fail problem. When drug shortages threaten, the agency may allow noncompliant facilities to continue shipping medically necessary drugs rather than enforce recalls. This dynamic weakens enforcement incentives and reinforces quality management deficiencies at foreign facilities.
Recent months saw multiple recalls from Indian manufacturers. Lupin Limited recalled 2.5 million bottles of eye medication in June 2026. Zydus recalled 22,000 bottles of cholesterol drugs in December 2025. The pattern suggests quality control problems extend beyond single facilities to systemic issues in overseas production hubs.
Americans trust that medications they take have been verified by FDA quality control professionals. The Amgen recall demonstrates that assumption is becoming harder to defend as inspection capacity fails to keep pace with pharmaceutical manufacturing globalization. With minimal independent testing and announced inspections, contaminated drugs reach patients before regulators detect problems.
The foreign substance on Corlanor tablets was never identified. The FDA classified the risk as remote but acknowledged potential for temporary harm. For heart failure and kidney disease patients dependent on these medications, remote risks become tangible threats when oversight systems falter.